Last reviewed · How we verify
NCT03309735
Non-interventional Study of Therapy for Threatened Miscarriage
trial testing Micronized progesterone in Threatened Miscarriage in 1,241 participants. Completed in 22 December 2017.
22 December 2017
Quick facts
| Lead sponsor | Besins Healthcare |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,241 |
| Start date | 16 October 2017 |
| Primary completion | 22 December 2017 |
| Estimated completion | 22 December 2017 |
| Sites | 17 locations across Russia |
Drugs / interventions tested
- Micronized progesterone
- Micronized progesterone
- Dydrogesterone (DYDROGESTERONE) — full drug profile →
Conditions studied
- Threatened Miscarriage — all drugs for Threatened Miscarriage →
Sponsor
Besins Healthcare
Who can join
Adults 18 to 35, female only, with Threatened Miscarriage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study the efficacy and safety of therapy for threatened miscarriage with medicinal products Utrogestan (micronized progesterone), 200 mg capsules (Besins Healthcare SA, Belgium), and Duphaston (Dydrogesterone), 10 mg coated tablets (Abbott Healthcare Products B.V., the Netherlands)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03309735
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Micronized progesterone
Trials testing the same drug.
- NCT05997563 — Adjunctive Vaginal Progesterone in Management of Preterm Labor · Phase 4 · unknown
- NCT04597099 — Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion · EARLY_PHASE1 · unknown
- NCT04758871 — Oral Versus Vaginal Progesterone for Luteal Phase Supplementation in Frozen Embryo Transfer Cycles · Phase 4 · completed
- NCT04225221 — Neurobiology of Bulimia Nervosa · Phase 2 · completed
- NCT04051320 — Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model · Phase 2 · completed
Other Besins Healthcare trials
Trials by the same sponsor.
- NCT03437109 — Efficacy of Androgen Substitution for Hypogonadism in Men With Type 2 Diabetes Mellitus · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03309735 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Besins Healthcare
- Last refreshed: 18 January 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03309735.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing